- Open Access
Response to comment on: Gleicher N et al., 2016. Reprod biol endocrinol Sep 5;14(1):54
© The Author(s). 2017
Received: 17 March 2017
Accepted: 17 March 2017
Published: 5 April 2017
We appreciate the interest of Tiegs et al. in our manuscript  but find the criticism surprising. When we wrote our paper, their abstract had been published in 2015 in Fertility&Sterility . It, therefore, was appropriately referenced, while their full length manuscript, in contrast, had not yet been published and, therefore, was at the time unknown to us. The manuscript appeared only at the end of July . Had we known of the manuscript we, of course, would have quoted the full length manuscript, rather than the abstract, though both in the end offered the same data set, out of a total of 525 embryo transfers, reporting on only 5 alleged clinical misdiagnoses that were reanalyzed.
It is important to note that, therefore, only these 5 cases (and not 525 cases) underwent a second preimplantation genetic screening (PGS) testing round, thereby offering the opportunity to reevaluate only these cases for the possible presence of mosaicism. It is also noteworthy that this repeat testing was done with the same testing platform as before, array genomic hybridization (aCGH), which since has been declared “inadequate” for PGS testing by the PGD International Society (PGDIS) since aCGH cannot reliably detect mosaicism . We will further discuss this fact below in more detail. Based on the repeat testing round, Tiegs et al. concluded that 2/5 embryos (40%) were mosaic because repeat testing gave different results.
The remaining 520 embryos were, however, not reexamined. To, therefore, suggest that the mosaicism rate was 2/525 rather than 2/5 is incorrect. The authors, of course, have no way of knowing to what degree results of a second testing round of these 520 embryos would have differed from the first round.
As the results of our study demonstrated, even within the same PGS laboratory multiple embryo biopsies from same embryos diverged in approximately 50 percent of embryos . Others reported similar outcomes from multiple biopsies , and even the PGDIS has acknowledged this fact .
We, of course, do acknowledge that five embryos represent a small sample size but, until publication of our study , the literature really offered almost no data on embryos undergoing repeat and/or multiple biopsies. Even our study only reported on 11 embryos that underwent repeat biopsies. Tiegs et al., however, factually misrepresented our manuscript in their letter to the editors when claiming that we failed to point out that their study included only five cases. Very much to the contrary, this is exactly what we did when writing: “The small number of evaluated embryos (referring to our study) does not allow ultimate conclusions about what likely mosaicism rates in human embryos may be. Here presented data do, however, suggest that they are significantly higher than the 4.8% rate recently detected by Greco et al. [reference] and more in line with the 2/5 (40%) recently reported by Tiegs et al. [Reference].” We, thus, very clearly pointed out the small number of cases in their report.
Because the basic concept of PGS is being questioned on theoretical, experimental and clinical grounds, our specialty is currently in the midst of an at times unfortunately vitriolic dispute about the clinical value of PGS. The work of our, an Italian  and an Israeli group  basically forced the PGDIS in July of this year to radically redefine how PGS results should be reported out . In revised guidelines the PGDIS fully acknowledges that mosaicism at blastocyst stage is apparently much more frequent than has previously been acknowledged. The society, however, also points out that the only platform that should be used in PGS is NGS (Next Generation Sequencing) since, it alone, can detect mosaicism above a 20% threshold in a single trophectoderm biopsy. In other words, aCGH (used in the study by Tiegs et al.), has been disavowed by the society because it underestimates mosaicism rates.
Moreover, the society now defines up to 80% mosaicism in a single trophectoderm biopsy as “normal mosaic,” establishing such embryos, therefore, as potentially transferrable. This alone demonstrates that the claim by Tiegs et al. of a 0.7% mosaicism rate in trophectoderm biopsies is unsustainable. That they make this claim based on newborn testing also demonstrates that they have not taken into consideration recent data that demonstrate the incredible ability of (at least rodent) embryos to self-correct downstream from blastocyst stage . Moreover they, likely also did not consider that the trophectoderm, from which biopsies are taken for PGS, becomes the placenta, which for decades has been known to be riddled with aneuploid clonal cell island and, therefore, very obviously is mosaic, even if the fetus, arising from the inner cell mass, is not.
Availability of data and materials
NG wrote this response. All authors read and approved of the final manuscript.
NG, and DHB are co-inventors on a number of pending and already awarded US patents claiming therapeutic benefits from androgen supplementation in women with low functional ovarian reserve (LFOR) and relating to the FMR1 gene in a diagnostic function in female fertility. Both receive royalties from Fertility Nutraceuticals, LLC, in which NG also holds shares. NG, DHB and VAK also are co-inventors on two pending AMH-related patent application. They report no other potential conflicts with here reported manuscript. All other authors report no potential conflicts with here reported manuscript.
Consent for publication
Ethics approval and consent to participate
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Gleicher N, Vidali A, Braverman J, Kuhnir VA, Barad DH, Hudson C, Wu Y-G, Wang Q, Zhang L, Albertini DF, International PGS Consortium Study Group. Accuracy of preimplantation genetic screening (PGS) is compromised by degree of mosaicism of human embryos. Reprod Biol Endocrinol. 2016;14:54.View ArticlePubMedPubMed CentralGoogle Scholar
- Tiegs AW, Hodge-Wertz B, McCulloh DH, Grifo J. Clinical error rate of array comparative genomic hybridization (ACGH) in euploid blastocysts. Fertil Steril. 2015;104 Suppl 3:e275. abstract.View ArticleGoogle Scholar
- Tiegs AW, Hodes-Wertz B, McCulloh DH, Munné S, Grifo JA. Discrepant diagnosis rate of array comparative genomic hybridization in thawed euploid blastocysts. J Assist Reprod Genet. 2016;33:893–7.View ArticlePubMedGoogle Scholar
- PGDIS Newsletter, PGDIS Position Statement on Chromosome Mosaicism and Preimplantation Aneuploidy Testing at the Blastocyst Stage, Chicago; 2016; pgdis.org. Accessed 30 July 2016.Google Scholar
- Orvieto R, Shuly Y, Brengauz M, Feldman B. Should pre-implantation genetic screening be implemented to routine clinical practice? Gynecol Endocrinol. 2016;32:506–8.View ArticlePubMedGoogle Scholar
- Greco E, Minasi G, Fiorentino F. Healthy babies after intrauterine transfer of mosaic aneuploid blastocysts. N Engl J Med. 2015;373:2089–90.View ArticlePubMedGoogle Scholar
- Bolton H, Graham SJL, Van der Aa N, Kumar P, Theunis K, Gallardo EF, Voet T, Zernicka-Goetz M. Mouse model of chromosome mosaicism reveals lineage-specific depletion of aneuploid cells and normal development potential. Nat Commun. 2016;7:11165.View ArticlePubMedPubMed CentralGoogle Scholar